This research aims to assess the relationship between GLP-1 receptor agonist use and vertebral fracture risk in individuals with type 2 diabetes.
Cohort study design
Analyzed prescriptions of semaglutide, liraglutide, or dulaglutide
Evaluated occurrences of vertebral fractures and related surgical procedures
Increased vertebral fracture risk identified among patients using semaglutide and dulaglutide
Related surgical procedures observed in cohort
Findings indicate the need for monitoring fracture risk in patients on these medications
Abstract
This cohort study examines the association of semaglutide, liraglutide, or dulaglutide prescriptions with vertebral fractures and related surgical procedures among patients with type 2 diabetes.